RYE, N.Y., Sept. 22, 2015 — Curemark LLC, announced today that CEO and founder Dr. Joan Fallon will present a Power Talk at the Athena Center for Leadership Studies at Barnard College on Tuesday, September 29. Dr. Fallon is an Athena Distinguished Fellow.
The Athena Center for Leadership Studies was established in Fall 2009 and is dedicated to the advancement of courageous and inspiring women leaders around the world.
“I’m grateful to the Athena Center for the opportunity to participate in a Power Talk,” Dr. Fallon said. “I am eager to share my personal and professional journey from practitioner to biotech CEO, and where the paths of entrepreneurship, leadership, innovation and technology intersect.”
Curemark is a biopharmaceutical company focused on the development of novel therapies to treat serious diseases. The company recently announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism.
Dr. Fallon will be speaking and taking questions from 7:00-8:30 p.m. To learn more about the talk, visit the event page. To register, click here.
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com.
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.